CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 114 enrolled
Drug / intervention
Methylene Blue MMX 25 mg modified release tabletsdrug
Likely dose
Methylene Blue MMX 25 mg modified release tabletsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03287219
NCT03287219Phase 2Completed
CompareCT.gov

Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX® Modified Release Tablets Administered to Patients Undergoing Colonoscopy

Cosmo Technologies Ltd·interventional·Posted Sep 19, 2017·Updated Jan 28, 2021

In Brief

A Phase 2 clinical trial evaluating Methylene Blue MMX 25 mg modified release tablets for Colon Staining in Preparation for Colonoscopy. Completed, enrolled 114 participants.

Detailed Summary

To describe and evaluate the mucosal staining efficacy of Methylene Blue MMX® tablets after total oral doses of 150 or 200 mg in patients undergoing a full colonoscopy for various reasons.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColon Staining in Preparation for Colonoscopy
Countries--
CollaboratorsCross S.A.

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 19, 2017
Enrollment StartMay 2, 2011
Primary CompletionJan 16, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 8.8 years ago

Interventions

Methylene Blue MMX 25 mg modified release tabletsdrug

Methylene Blue MMX 25 mg modified release tablets administered with a full dose regimen of a 4-L PEG-based bowel cleansing preparation.